Company intelligence / Profile preview
Ambrilia Biopharma Inc.
Montreal, Quebec, Canadaambrilia.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Completed Phase 3 trials for Octreotide formulation C2L for acromegaly with positive results showing safety and efficacy, with the ability to replace Sandostatin LAR with less frequent injections and non-inferior efficacy on Growth Hormone and Insulin-like Growth Factor 1
- Therapeutic areas
- OncologyEndocrinologyInfectious Diseases
- Modalities
- Peptidessmall molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Merck & Co. ($232 million deal for PPL-100)TEVA Europe (licensing/distribution for Octreotide)Covidien Ltd. (terminated)TaiMed Biologics (took over rights for protease inhibitor and integrase inhibitor programs)
Beyond the preview
Go deeper on Ambrilia Biopharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambrilia Biopharma Inc..